No products in the cart.
Pre-made Quilizumab benchmark antibody ( Whole mAb, anti-IGHE/IgE therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-462
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Quilizumab biosimilar, Whole Mab: Anti-IGHE/IgE therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Quilizumab (INN) is a humanized monoclonal antibody designed for the treatment of asthma.[1] It binds to IGHE.
| Products Name (INN Index) | Pre-Made Quilizumab biosimilar, Whole Mab: Anti-IGHE/IgE therapeutic antibody |
|---|---|
| INN Name | Quilizumab |
| Target | IGHE |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | 3hr5:HL:JQ:BA:IP |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2011 |
| Year Recommended | 2012 |
| Companies | Genentech |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Allergic asthma,Allergic rhinitis,Urticaria |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | IGHE |
| Package |
Previous slide
Next slide
